NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer

Clinical Cancer Research

Volumn 23, Issue 15, 2017, Pages 4055-4065

  Ma, Cynthia X ^a   Gao, Feng ^b   Luo, Jingqin ^b   Northfelt, Donald W ^c   Goetz, Matthew ^d   Forero, Andres ^e   Hoog, Jeremy ^a   Naughton, Michael ^a   Ademuyiwa, Foluso ^a   Suresh, Rama ^a   Anderson, Karen S ^c   Margenthaler, Julie ^a   Aft, Rebecca ^a   Hobday, Timothy ^d   Moynihan, Timothy ^d   Gillanders, William ^a   Cyr, Amy ^a   Eberlein, Timothy J ^a   Hieken, Tina ^d   Krontiras, Helen ^f   Guo, Zhanfang ^a   Lee, Michelle V ^a   Spies, Nicholas C ^a   Skidmore, Zachary L ^a   Griffith, Obi L ^a   Griffith, Malachi ^a   Thomas, Shana ^a   Bumb, Caroline ^a   Vij, Kiran ^a   Huang Bartlett, Cynthia ^g   Koehler, Maria ^g   Al Kateb, Hussam ^a   Sanati, Souzan ^a   Ellis, Matthew J ^h   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c MAYO CLINIC   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Kentucky   (United States)

^g PFIZER INC   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; KI 67 ANTIGEN; PALBOCICLIB; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; ANTINEOPLASTIC AGENT; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; NITRILE; PIK3CA PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE REGULATION; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG SAFETY; DRUG WITHDRAWAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LEUKOPENIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEOADJUVANT THERAPY; NEUTROPENIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PIK3CA GENE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RASH; SIDE EFFECT; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MUTATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL PROLIFERATION; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; NEOPLASM STAGING; NITRILES; PIPERAZINES; PYRIDINES; RECEPTOR, ERBB-2; TRIAZOLES;

EID: 85018518861     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-3206     Document Type: Article

References (49)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672–7.
2. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501–12.
3. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993;262:2050–4.
4. Weinberg R. The retinoblastoma protein and cell cycle control. Cell 1995;81:323–30.
5. Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature 1992;358:259–61.
6. Altucci L, Addeo R, Cicatiello L, Germano D, Pacilio C, Battista T, et al. Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. Endocrinology 1997;138:978–84.
7. Geum D, Sun W, Paik SK, Lee CC, Kim K. Estrogen-induced cyclin D1 and D3 gene expressions during mouse uterine cell proliferation in vivo: Differential induction mechanism of cyclin D1 and D3. Mol Reprod Dev 1997;46:450–8.
8. Said TK, Conneely OM, Medina D, O'Malley BW, Lydon JP. Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endocrinology 1997;138:3933–9.
9. Tong W, Pollard JW. Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Mol Cell Biol 1999;19:2251–64.
10. Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, et al. Therapeutically activating RB: Reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer 2011;18:333–45.
11. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427–38.
12. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.
13. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:1925–36.
14. Finn RS, Crown JP, Ettl J, Schmidt M, Bondarenko IM, Lang I, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: Expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res 2016;18:67.
15. Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015;373:209–19.
16. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol 2015;16:25–35.
17. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380–8.
18. Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: Results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol 2017:JCO2016694406.
19. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol 2011;29:2342–9.
20. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16: 5222–32.
21. Ma CX, Luo J, Naughton M, Ademuyiwa F, Suresh R, Griffith M, et al. A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor–positive metastatic breast cancer. Clin Cancer Res 2016;22:1583–91.
22. Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, et al. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun 2016;7:12498.
23. Griffith M, Griffith OL, Smith SM, Ramu A, Callaway MB, Brummett AM, et al. Genome modeling system: A knowledge management platform for genomics. PLoS Comput Biol 2015;11:e1004274.
24. Skidmore ZL, Wagner AH, Lesurf R, Campbell KM, Kunisaki J, Griffith OL, et al. GenVisR: Genomic visualizations in R. Bioinformatics 2016;32:3012–4.
25. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13–22.
26. Hochberg Y, Tamhane AC. Multiple comparison procedures. New York: John Wiley & Sons, Inc.; 2008.
27. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43:e47.
28. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007;23:257–8.
29. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
30. Ma Y, Yuan J, Huang M, Jove R, Cress WD. Regulation of the cyclin D3 promoter by E2F1. J Biol Chem 2003;278:16770–6.
31. Geng Y, Eaton EN, Picon M, Roberts JM, Lundberg AS, Gifford A, et al. Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 1996;12:1173–80.
32. Carcagno AL, Marazita MC, Ogara MF, Ceruti JM, Sonzogni SV, Scassa ME, et al. E2F1-mediated upregulation of p19INK4d determines its periodic expression during cell cycle and regulates cellular proliferation. PLoS One 2011;6:e21938.
33. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:353–60.
34. Gellert P, Segal CV, Gao Q, Lopez-Knowles E, Martin LA, Dodson A, et al. Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. Nat Commun 2016;7:13294.
35. Curigliano G, Gomez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, et al. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. The Breast 2016;28:191–8.
36. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554–9.
37. Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61–70.
38. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009;69:3955–62.
39. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, et al. ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011;1:338–51.
40. Ma CX, Crowder RJ, Ellis MJ. Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids 2011;76:750–2.
41. Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2016;17:811–21.
42. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425–39.
43. Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 2014;26:136–49.
44. Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer 2015;15:261–75.
45. Ma CX, Bose R, Ellis MJ. Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer. Adv Exp Med Biol 2016;882:125–54.
46. Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 2016;76:2301–13.
47. Miller WR, Larionov A, Anderson TJ, Evans DB, Dixon JM. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics J 2012;12:10–21.
48. Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, et al. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics 2007;17:813–26.
49. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007;9:R37.